ValuEngine upgraded shares of Gossamer Bio (NASDAQ:GOSS) from a hold rating to a buy rating in a report released on Thursday, ValuEngine reports.
Separately, Zacks Investment Research cut shares of Gossamer Bio from a buy rating to a hold rating in a research report on Wednesday, July 17th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Gossamer Bio currently has an average rating of Buy and an average target price of $28.00.
GOSS traded down $1.84 during trading on Thursday, reaching $18.57. 266,524 shares of the stock traded hands, compared to its average volume of 217,787. The company has a quick ratio of 19.79, a current ratio of 19.79 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $1.34 billion and a PE ratio of -0.82. The company has a 50-day simple moving average of $20.80. Gossamer Bio has a 12 month low of $15.59 and a 12 month high of $25.06.
Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.90) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.63) by ($0.27). Equities research analysts anticipate that Gossamer Bio will post -2.61 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently modified their holdings of GOSS. Omega Fund Management LLC bought a new stake in Gossamer Bio during the first quarter valued at $150,681,000. FMR LLC bought a new stake in Gossamer Bio during the first quarter valued at $26,576,000. Victory Capital Management Inc. bought a new stake in Gossamer Bio during the first quarter valued at $18,649,000. Federated Investors Inc. PA bought a new stake in Gossamer Bio during the first quarter valued at $15,992,000. Finally, Marshall Wace North America L.P. bought a new position in shares of Gossamer Bio during the 1st quarter worth about $9,523,000. 52.76% of the stock is currently owned by institutional investors and hedge funds.
Gossamer Bio Company Profile
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.
Further Reading: Do back-end load funds outperform no-load funds?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.